1.
|
Phase: Phase IV Type: Supportive care, Treatment Status: Completed Age: Over 18 Sponsor: Other Protocol IDs: CDR0000257189, AGOSG-OVAR-MO16375-MARCH, EU-20217, ROCHE-MO16375, ROCHE-RO2053859, NCT00046969
|
|
2.
|
Phase: Phase IV Type: Supportive care Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ML20197, NCT00776425
|
|
3.
|
Phase: Phase III Type: Treatment Status: Completed Age: Over 18 Sponsor: Other Protocol IDs: AVENTIS-FIN-1-2003, FINNISH-URO-OGS-1-2003, PROSTY-FIN-1-2003, ICORG-06-14-Prosty, EU-20891, NCT00255606
|
|
4.
|
Phase: Phase III Type: Supportive care Status: Closed Age: Over 16 Sponsor: Other Protocol IDs: BARTS-06/Q0605/93, ISRCTN11830961, EU-20731, 06/Q0605/93, NCT00482716
|
|
5.
|
Phase: Phase III Type: Supportive care, Treatment Status: Completed Age: 20 to 79 Sponsor: Pharmaceutical / Industry Protocol IDs: EPO316 JP, NCT00628043
|
|
6.
|
Phase: Phase II Type: Treatment Status: Completed Age: 61 to 75 Sponsor: Other Protocol IDs: BACOPP-21, NCT00284271
|
|
7.
|
Phase: Phase II Type: Supportive care Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: CDR0000574173, CHUL-NEOPALIA, RECF0359, NEOPALIA, NCT00559195
|
|
8.
|
Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ML20559, NCT00551291
|
|
9.
|
Phase: No phase specified Type: Supportive care, Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR003460, EPOSUR4001, NCT00264095
|